Aegerion Pharmaceuticals, Inc.' Lomitapide Receives Orphan Drug Designation in Japan for the Treatment of Homozygous Familial Hypercholesterolemia
Published: Sep 09, 2013
CAMBRIDGE, Mass., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the company has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for lomitapide for the treatment of homozygous familial hypercholesterolemia (HoFH).
Help employers find you! Check out all the jobs and post your resume.